semaglutide for type 2 diabetes drug improves weight loss, blood sugar in certain Type 1 patients with obesity Type 2 diabetes: New Ozempic

Theres no single perfect number for everyone, but many patients taking GLP-1 medications benefit from aiming for higher protein intake than they were eating previously

By route of administration, the oral segment is expected to command the highest share in the global anti-obesity drug market with 33.1% in 2026, predominantly because of patient preference and its convenience in daily use

Grocery shopping changes fundamentally because your preferences have shifted toward foods that support your new relationship with hunger and satiety

25 Balance model The Centers for Medicare and Medicaid Services (CMS) also announced the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model with aims to increase access to selected GLP-1s in Medicaid and Medicare

Clinical trial evidence includes small-scale studies and post-hoc analyses suggesting possible benefits